Estrogen and Bone Loss: Why Menopause Changes Bone Density and Fracture Risk

Bone loss often accelerates during and after menopause, and one of the major reasons is the decline in estrogen. Estrogen helps regulate normal bone remodeling. As estrogen levels fall, bone breakdown can begin to outpace bone formation, increasing the likelihood of osteopenia, osteoporosis and fractures.

That relationship is important, but it can also become oversimplified. Bone health is not determined by estrogen alone. Muscle mass, protein intake, resistance training, calcium and vitamin D adequacy, body composition, medications, smoking, alcohol use, inflammatory disease and fall risk all influence what happens to the skeleton over time.

At HormoneSynergy®, we look at menopause-related bone loss within that larger longevity framework. The question is not only whether bone density is declining. It is what may be driving the change, what can be measured, and which interventions are most likely to preserve strength and mobility over the years ahead.

Why Estrogen Matters for Bone Health

Bone is living tissue. Throughout adulthood, old bone is continually removed and new bone is formed. Estrogen is involved in regulating that remodeling process and helps restrain excessive bone resorption.

When estrogen declines around menopause, the balance shifts. Bone turnover increases, and for many women the rate of bone loss becomes more rapid than it was during the earlier adult years. This is one reason osteoporosis becomes considerably more common after menopause.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases identifies low estrogen after menopause as an important osteoporosis risk factor. The change can begin around the menopausal transition rather than suddenly appearing years later.

Menopause Is Also a Skeletal Transition

Menopause is usually discussed in terms of hot flashes, sleep disruption, mood, sexual function and changes in menstrual cycles. The skeleton is undergoing its own transition at the same time.

Estrogen decline can accelerate bone turnover while other midlife changes may compound the problem. Muscle mass may begin to fall. Physical activity can decline. Insulin resistance and visceral fat may increase. Some women eat less protein than they need, and others have inadequate calcium or vitamin D intake. Medications or medical conditions may further affect bone.

This is why the menopausal transition is a useful time to think about bone before osteoporosis is advanced rather than waiting for a fracture to make the problem visible.

Osteopenia, Osteoporosis and Fracture Risk

Lower estrogen does not mean that every postmenopausal woman will develop osteoporosis. It does mean that one of the major physiologic protections against accelerated bone resorption has changed.

Bone density may move gradually from a normal range into osteopenia and, in some people, eventually into osteoporosis. The clinical concern is not the diagnostic label by itself. It is fracture.

Fragility fractures commonly involve the hip, spine, wrist and shoulder. Hip and vertebral fractures can have lasting consequences for mobility and independence, particularly later in life. A hip fracture is not simply a broken bone that eventually heals. Many older adults never fully regain their previous level of mobility afterward.

Fracture risk also cannot be read from bone density alone. Age, previous fractures, family history, smoking, alcohol exposure, body weight, medications, balance and fall risk all contribute.

When Bone Density Testing Matters

DEXA, or dual-energy X-ray absorptiometry, measures bone mineral density and can identify loss of bone mass before a major fracture occurs.

The USPSTF's 2025 recommendation advises osteoporosis screening for women age 65 and older. It also recommends screening postmenopausal women younger than 65 when clinical risk assessment indicates increased fracture risk. For men, the USPSTF continues to conclude that the available evidence is insufficient to establish a routine population-screening recommendation.

For younger postmenopausal women, factors such as low body weight, parental history of hip fracture, cigarette smoking and excessive alcohol use can help identify women who warrant formal risk assessment. Other medical conditions and medications can create additional reasons for earlier evaluation.

DEXA becomes particularly relevant when menopause is accompanied by a prior fracture, family history of osteoporosis, low body weight, prolonged steroid exposure, smoking, early menopause or another condition associated with bone loss.

HormoneSynergy® offers Hologic® DEXA testing that evaluates bone density together with whole-body composition, lean mass, fat distribution and visceral fat. Learn more about DEXA Bone Density & Visceral Fat Testing.

Early Menopause Deserves Particular Attention

The age at which estrogen declines matters. Women who experience premature ovarian insufficiency or menopause substantially earlier than the usual age of natural menopause spend more years with lower estrogen exposure.

That longer period can affect bone health. Current menopause guidance recognizes bone protection as one of the reasons menopausal hormone therapy is generally considered in women with premature ovarian insufficiency who do not have a contraindication, typically through the usual age of natural menopause.

Early menopause therefore deserves more than symptom management. Bone density, cardiovascular risk, hormone history and the broader consequences of early estrogen loss should be considered together.

Does Menopausal Hormone Therapy Help Bone Density?

Yes. Menopausal hormone therapy can prevent postmenopausal bone loss and reduce fracture risk in appropriately selected women.

That does not make hormone therapy a universal osteoporosis treatment or mean that every woman with declining bone density should begin estrogen. Hormone therapy decisions also involve menopausal symptoms, age, timing since menopause, cardiovascular history, thrombotic risk, breast history, uterine status and individual treatment goals.

The more useful question is not whether estrogen is “good” or “bad” for bone. Its skeletal effects are well established. The clinical question is whether hormone therapy is an appropriate part of the larger plan for a particular woman.

For the broader HormoneSynergy® approach, see Hormone Transitions: Perimenopause, Menopause & Andropause.

Estrogen Is Important, but It Is Not the Whole Story

A woman can use estrogen and still lose bone if other important factors are being missed. Conversely, bone-health interventions do not stop being important simply because hormone therapy is being used.

Protein intake matters because bone and muscle are structurally and functionally connected. Resistance training provides mechanical loading that helps preserve both tissues. Calcium must be available for mineralization. Vitamin D is involved in calcium absorption and skeletal physiology. Smoking, excessive alcohol use and some medications can adversely affect bone.

Body composition belongs in the conversation as well. Muscle provides mechanical loading and contributes to balance, mobility and the ability to prevent a fall from becoming a fracture.

Our Body Composition & Longevity Medicine guide explains why body weight alone cannot distinguish lean mass from fat mass. For a closer look at that distinction, see Lean Mass vs Fat Mass: Why Weight Alone Misleads in Longevity Medicine.

Protecting Bone During and After Menopause

Resistance Training and Weight-Bearing Exercise

Exercise is one of the places where bone and muscle health meet directly. Resistance training challenges muscle while also placing mechanical stress on bone. Weight-bearing movement and, when appropriate, impact exercise provide additional skeletal loading.

The appropriate program depends on current fitness, balance, fracture history, osteoporosis severity and orthopedic limitations. Someone with advanced osteoporosis may need a different program from someone establishing a baseline during early menopause.

Protein, Calcium and Vitamin D

Bone health is sometimes reduced to calcium supplementation. That misses much of the physiology.

Calcium is essential, but protein and vitamin D are also important. Whenever practical, calcium should begin with an assessment of food intake rather than an assumption that everyone needs the same supplement dose. Protein requirements deserve particular attention in midlife because preservation of muscle becomes increasingly important with age.

Vitamin D is relevant to bone health, but supplementation and testing should be individualized rather than driven by the assumption that higher is always better. Our Vitamin D3 and K2: Do You Really Need Them Together? article looks more closely at calcium metabolism and the popular claim that vitamin D must always be paired with K2.

For a broader discussion of when supplements make sense, see What Vitamins Should I Take? An Evidence-Based Guide to Supplements, Nutrient Gaps, Testing & Safety.

Muscle and Fall Prevention

Fracture prevention is partly a bone problem and partly a fall problem. Stronger legs, better balance, adequate vision, appropriate footwear, a safe home environment and review of medications that cause dizziness or sedation can all influence fracture risk.

Muscle therefore deserves its own attention. Preserving lean mass supports mobility and balance while also providing the mechanical loading that bone needs.

Hormone-Informed Evaluation

Women with early menopause, significant menopausal symptoms, declining bone density or a broader pattern of hormone-related concerns may benefit from a more complete discussion of hormone therapy and other medical options.

Hormone evaluation should not be separated from cardiovascular risk, metabolic health, breast history, uterine status, medications and the woman's own treatment priorities.

Use DEXA and Clinical Risk Together

A DEXA result is useful because it provides objective information. It is not the entire fracture-risk assessment.

Age, previous fracture, menopause timing, family history, body weight, medications, smoking, alcohol, muscle strength, falls and other health conditions all add information that a T-score cannot provide by itself.

Bone Health in Longevity Medicine

A longevity medicine approach to menopause-related bone loss brings several pieces together rather than treating them as unrelated problems. DEXA can establish bone density and help track change. Whole-body composition can show whether lean mass is being preserved. Nutrition can be evaluated for protein, calcium and vitamin D adequacy. Exercise can be designed around both muscle and skeletal loading.

Hormone therapy may be part of that plan for an appropriate patient. Other women may need osteoporosis-specific medication or evaluation for secondary causes of bone loss. Supplements may be useful when they address an actual nutritional gap, but they should not substitute for diagnosis, DEXA or appropriate medical treatment.

If nutritional supplementation is being considered, the HormoneSynergy® Supplement Guide & Clinical Catalog organizes vitamins, minerals, bone-support formulas, protein, creatine and other professional supplements by clinical purpose.

Related HormoneSynergy® Services

• DEXA Bone Density & Visceral Fat Analysis
• Hormone Optimization and Bioidentical Hormone Therapy
• Personalized Longevity Medicine
• Weight Loss for Longevity

Portland and Lake Oswego Menopause Bone Health

For women in Portland, Lake Oswego and surrounding communities, menopause-related bone loss can be addressed before a fracture occurs. DEXA testing can establish a baseline or identify declining bone density, while body-composition testing adds information about lean mass and visceral fat that a standard scale cannot provide.

The larger assessment still matters. Menopause timing, family history, previous fractures, exercise, nutrition, medications, hormone therapy and fall risk all contribute to the decisions that follow. The objective is not simply to preserve a number on a report. It is to preserve strength, posture, mobility and independence.

Frequently Asked Questions

Why does estrogen loss affect bone density?

Estrogen helps regulate normal bone remodeling. As estrogen declines around menopause, bone resorption can increase and bone loss may accelerate.

Does menopause increase osteoporosis risk?

Yes. Declining estrogen is one important reason osteoporosis becomes more common after menopause, although age, genetics, body weight, medications, smoking, alcohol, nutrition, muscle mass and physical activity also influence risk.

Can hormone therapy help prevent bone loss?

Yes. In appropriately selected women, menopausal hormone therapy can prevent postmenopausal bone loss and reduce fracture risk. Whether hormone therapy is appropriate depends on the woman's age, symptoms, medical history, timing since menopause, contraindications and treatment goals.

When should postmenopausal women consider a DEXA scan?

The USPSTF recommends osteoporosis screening for women age 65 and older and for postmenopausal women younger than 65 who are found to be at increased fracture risk after clinical risk assessment. Individual medical conditions, medications and fracture history may create additional reasons for earlier evaluation.

Is estrogen the only factor in menopause-related bone loss?

No. Protein intake, calcium and vitamin D adequacy, muscle mass, resistance training, body weight, smoking, alcohol, medications, medical conditions and fall risk all influence bone health.

Selected References

1. U.S. Preventive Services Task Force. Osteoporosis to Prevent Fractures: Screening. Final Recommendation Statement. January 14, 2025.
2. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteoporosis: Causes, Risk Factors, and Symptoms.
3. The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society.
4. The Menopause Society. Management of Osteoporosis in Postmenopausal Women: 2021 Position Statement.

This article is for educational purposes only and is not a substitute for individualized medical advice, diagnosis or treatment.